Epilepsy and Seizure Medication
  Novartis Pharma US

 




Trileptal Speakers - The eSlide library provides approved promotional slides to trained TRILEPTAL speakers. Enter eSlide Library

Novartis Medicare Resource Center

Patient Assistance Program - visit www.pap.novartis.com

First-line Use

For most patients, Monotherapy is a realistic goal for treatment -Kwan/Brodie1

More patients achieved 100% reduction in seizure frequency with their first antiepileptic drug (AED) monotherapy than with their second monotherapy1


 Woman with Headphones
Adult Efficacy
Pediatric Efficacy
First-line Use
TRILEPTAL vs CBZ
Single-center, prospective study of 525 children, adolescents, and adults initially diagnosed with epilepsy, who were treated with a single AED when possible and followed between the years 1984 and 1997 at the Epilepsy Unit of the Western Infirmary in Glasgow, Scotland. Seizures were classified as generalized convulsive (eg, tonic, clonic, or tonic-clonic), nonconvulsive (eg, absence or myoclonic), or partial (focal). Patients were considered to be free of seizures if they had not had seizures of any type for a minimum of 1 year while receiving the same dose of AED, or while not taking any medication.1

Among 470 patients who had never received an AED, 47% achieved 100% reduction in seizure frequency with their first AED
Only 13% of patients achieved 100% reduction in seizure frequency with a second monotherapy AED


TRILEPTAL monotherapy: Seizure reduction at weeks 1, 5, 9, and 13

Percentage of patients with newly diagnosed and recent onset partial seizures experiencing reduction in frequency of partial seizures at weeks 1, 5, 9, and 132

Reduction in frequency of partial seizures with TRILEPTAL monotherapy

Graph - Reduction in frequency of partial seizures with Trileptal monotherapy
At weeks 1, 5, 9, and 13, respectively, the number of TRILEPTAL-treated patients who experienced 50% reduction was 18, 20, 21, and 20; for placebo, the corresponding numbers were 16, 16, 15, and 14. At weeks 1, 5, 9, and 13, respectively, the number of TRILEPTAL-treated patients who experienced ≥75% reduction was 17, 17, 18, and 18; for placebo, the corresponding numbers were 15, 10, 9, and 9. At weeks 1, 5, 9, and 13, respectively, the number of TRILEPTAL-treated patients who experienced 100% reduction was 17, 15, 13, and 11; for placebo, the corresponding numbers were 13, 8, 5, and 5.

Multicenter, randomized, double-blind, placebo-controlled trial of 67 untreated patients (8 to 69 years of age) with newly diagnosed and recent-onset partial seizures. Patients were randomized to placebo or TRILEPTAL, initiated at 300 mg BID and titrated to 1200 mg/day (given as 600 mg BID) in 6 days, followed by maintenance treatment for 84 days. Except where noted, points were not statistically significant.2

56% of TRILEPTAL-treated patients experienced a ≥50% reduction in frequency of partial seizures at week 1 compared with 46% of patients in the placebo group2‡

— 53% of patients experienced ≥75% reduction (versus 43% for placebo)‡
— 53% of patients experienced 100% reduction (versus 37% for placebo)‡
66% of TRILEPTAL-treated patients experienced a ≥50% reduction in frequency of partial seizures at week 9 compared with 43% of patients in the placebo group2‡

— 56% of patients experienced ≥75% reduction (versus 26% for placebo)*
— 41% of patients experienced 100% reduction (versus 14% for placebo)†

Learn about the efficacy of TRILEPTAL monotherapy

*P=.0156 vs placebo.
†P=.0246 vs placebo.
‡P=NS.

References:
1. Kwan P, Brodie MJ. Early identification of refractory epilepsy. N Engl J Med. 2000;342:314-319.
2. Data on file. Novartis Pharmaceuticals Corporation, East Hanover, NJ.


E-mail this page  | Print this page





Novartis Pharma US Use of website is governed by the Terms of Use and Privacy Statement .
Copyright ©2008 Novartis Pharmaceuticals Corporation. All rights reserved.